Biology subjects

Ang, A.

Publications and source records attributed to Ang, A..

4 recordsLinked to original sources

bioRxiv2026

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

BackgroundPancreatic ductal adenocarcinoma (PDAC) is a particularly lethal malignancy with few treatment options available. Extensive remodelling of extracellular matrix (ECM) generates a highly fibrotic tumour landscape, which impairs therapeutic response. ObjectiveWe investigated whether stromal priming via the highly specific Focal Adhesion Kinase (FAK) inhibitor narmafotinib (AMP945) in combination with the two major standard-of-care chemotherapies in PDAC, gemcitabine/Abraxane and FOLFIRINOX, reduces fibrosis and enhances treatment efficacy. Design3D organotypic matrices, intravital imaging, and in vivo subcutaneous and orthotopic PDAC models were used to provide a rationale for a first-line priming regimen of narmafotinib prior to chemotherapy. ResultsNeoadjuvant chemotherapy induces fibrosis in PDAC indicating a need for upfront first-line priming of the ECM to normalise the stroma for optimal treatment response. Narmafotinib is a new potent small molecule FAK inhibitor. Phase I safety data shows excellent safety, tolerability, and pharmacokinetics following oral administration in humans. We reveal that narmafotinib treatment during early ECM remodelling ( priming) reduces fibrosis, while limiting subsequent PDAC invasion. Moreover, intravital imaging demonstrates real-time FAK inactivation and cell cycle stalling, leading to improved chemotherapeutic efficacy upon narmafotinib priming in vivo. Long-term assessment in patient-derived models shows that narmafotinib priming prior to gemcitabine/Abraxane or FOLFIRINOX reduces PDAC progression and extends survival in both chemotherapy settings. ConclusionsOur results using these Phase II-ready drug combinations strongly support the clinical assessment of narmafotinib in PDAC. Narmafotinib is currently in Phase Ib/IIa trials, assessing a pulsed dosing regimen prior to gemcitabine/Abraxane, and warrants further clinical assessment in combination with FOLFIRINOX. SIGNIFICANCE OF THIS STUDYO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIPancreatic cancer (PC) is one of the most lethal malignancies and is characterised by a dense, fibrotic stroma, which impairs chemotherapy efficacy. C_LIO_LIThe non-receptor tyrosine kinase FAK is known to promote cancer fibrosis and therefore represents a therapeutic target to normalise the PC stroma and to improve chemotherapy performance. C_LI What this study addsO_LINeoadjuvant chemotherapy induces early fibrosis indicating a need for upfront first-line priming of the ECM to blunt or normalise stromal fibrosis for optimal response to therapy. C_LIO_LIThe small molecule inhibitor narmafotinib (which is currently under Phase Ib/IIa clinical trial assessment) shows high specificity towards FAK as well as desirable pharmacokinetics and pharmacodynamics in healthy human volunteers. C_LIO_LIEarly short-term narmafotinib priming reduces fibrosis and improves the efficacy of subsequent standard-of-care gemcitabine/Abraxane chemotherapy. C_LIO_LIFOLFIRINOX (oxaliplatin, irinotecan, leucovorin and 5-fluorouracil) is a multi-agent chemotherapy preferentially used in PDAC patients with good performance status. Our results demonstrate that narmafotinib priming also improves FOLFIRINOX efficacy, leading to extended survival in patient-derived PDAC models. C_LI How this study might affect research, practice, or policyO_LIThis study supports the clinical development of narmafotinib in combination with both gemcitabine/Abraxane (ACCENT trial) and further FOLFIRINOX standard-of-care chemotherapies for PDAC patient treatment. C_LIO_LIThe first-line priming strategy and early ECM normalisation used in this study may also be applicable to other combination therapy settings and warrants further investigation in ongoing clinical studies. C_LI

cancer biology↗

bioRxiv2026

From time-course expression to gene regulation: direct linear ODE inference without finite-difference approximation

Inferring gene regulation from time-course expression profiles is essential for understanding how cells transition between states during development, differentiation, and disease progression. Existing approaches often model expression dynamics with ordinary differential equations (ODEs). However, due to the computational complexity of directly solving these ODE models, most methods rely on finite-difference approximations of temporal derivatives, which can amplify measurement noise, introduce discretization bias, and lead to unstable or biased parameter estimates. To fill this gap, we develop the first computational method to directly learn a linear ODE model for gene regulation inference without relying on finite-difference approximations. We first formulate an optimization problem that directly exploits the closed-form solution of the linear ODE system. We then solve this problem via gradient descent, deriving analytical gradients with respect to the model parameters; these gradients involve matrix exponentials and integrals, which are challenging to directly compute. To make the computation efficient, we further use high-order Taylor approximations of the gradients whose truncation error is on the order of machine precision. In addition, we establish theoretical results demonstrating an inherent, non-vanishing gap between our exact solution and solutions derived from finite-difference approximations, which underscores the theoretical advantages of our approach. Finally, we demonstrate that our method consistently outperforms competing approaches on both simulated data and real-world scRNA-seq datasets in terms of AUROC. Our source codes can be accessed here: https://github.com/EJIUB/ExactLinearODE

systems biology↗

bioRxiv2022

Analyzing the covariance structure of plasma signaling proteins in relation to the diagnosis of dementia

Numerous studies have shown that individuals with dementia have exhibited activation of inflammatory pathways in their brains. Typically, these studies use traditional and well-established regression methods for data analysis. In this paper, a new approach is introduced that utilizes the analysis of the covariance structure using methods related to the principal component analysis (PCA) theory. Eleven biomarkers related to neuroinflammation were used to determine the association with the onset of dementia. Various demographic covariates were adjusted to account for possible confounding effects of the covariance structure. Three hypothesis testing methods were considered to discern differences between partial covariance matrices for comparing power and Type I errors through simulation studies. Application of hypothesis testing methods using data from Framingham Heart Study (FHS) found significant differences in covariance matrices between the non-dementia and dementia groups.

neuroscience↗

bioRxiv2019

Faecal DNA to the rescue: Shotgun sequencing of non-invasive samples reveals two subspecies of Southeast Asian primates to be Critically Endangered species

A significant number of Southeast Asian mammal species described in the 19th and 20th century were subsequently synonymized and are now considered subspecies. Many are affected by rapid habitat loss and there is thus an urgent need to re-assess the conservation status based on species boundaries established with molecular data. However, such data are lacking for many populations and subspecies. We document via a literature survey and empirical study how shotgun sequencing of faecal DNA is a still underutilized but powerful tool for accelerating such evaluations. We obtain 11 mitochondrial genomes for three subspecies in the langur genus Presbytis through shotgun sequencing of faecal DNA (P. femoralis femoralis, P. f. percura, P. siamensis cf. cana). The genomes support the resurrection of all three subspecies to species based on multiple species delimitation algorithms (PTP, ABGD, Objective Clustering) applied to a dataset covering 40 species and 43 subspecies of Asian colobines. For two of the newly recognized species (P. femoralis, P. percura), the results lead to an immediate change in the IUCN status to Critically Endangered due to small population estimates and fragmented habitat. We conclude that faecal DNA should be more widely used for clarifying species boundaries in endangered mammals.

zoology↗